Treatment News : No Change in Rates of Transmitted Drug-Resistant HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 18, 2013

No Change in Rates of Transmitted Drug-Resistant HIV

CROI 2013The rate of drug-resistant HIV transmitted among newly diagnosed people has remained constant at about one in six cases, MedPage Today reports. Researchers with the Centers for Disease Control and Prevention (CDC) presented their most recent findings on the matter at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. The governmental health agency found that there was no significant increase in transmitted virus resistant to antiretrovirals between 2007, when the rate was 15 percent, to 2010, when it was 16.7 percent. However, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs, or “non-nukes”) is rising at an estimated rate of 5.2 percent per year.

The CDC sampled 18,144 HIV sequences from 77,887 newly diagnosed people with HIV at 10 U.S. surveillance sites between 2007 and 2010. Among these sequences, 2,932 (16.2 percent) had at least one resistance mutation: 2,461 of them showed resistance to one class of drugs, 386 to two classes, and 85 to three. Non-nuke resistance was the most common, with 1,464 mutations that yielded resistance to that class, followed by 1,205 to nucleoside reverse transcriptase inhibitors and 818 to protease inhibitors.

To read the MedPage Today story, click here.

Search: HIV, drug-resistance, MedPage Today, Centers for Disease Control and Prevention, CDC, 20th Conference on Retroviruses and Opportunistic Infections, CROI, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors, PIs, NNRTIs, NRTIs.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.